IsoRay, Inc. (NYSEMKT:ISR) skyrocketed 27.59% after the company announced that IASIS Medical has received formal approval for the sale of IsoRay’s complete product line in Greece. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $1.18 moved to $1.25 on last trade day and at the end of the day closed at $1.13. Company price to sales ratio in past twelve months was calculated as 9.44 and price to cash ratio as 9.87. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 43.04%.
Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 13, 2014 to file lead plaintiff applications in a securities class action lawsuit against Geron Corporation (NASDAQ:GERN). Geron Corporation (NASDAQ:GERN) shares fell -2.73% in last trading session and ended the day on $1.78. Geron Corporation (NASDAQ:GERN) return on equity ratio is recorded as -61.60% and its return on assets is -55.40%. Geron Corporation (NASDAQ:GERN) yearly performance is 57.52%.
Novavax, Inc. (NASDAQ:NVAX) on Mar. 10 reported its financial results for the fourth quarter and year ended December 31, 2013 and announced the initiation of a Phase 1/2 clinical trial of its H7N9 avian influenza VLP vaccine candidate with its proprietary Matrix-M adjuvant. Novavax, Inc. (NASDAQ:NVAX) shares moved down -2.05% in last trading session and was closed at $5.26, while trading in range of $5.06 – $5.60. Novavax, Inc. (NASDAQ:NVAX) year to date (YTD) performance is 2.73%.
OXiGENE Inc. (NASDAQ:OXGN) is a clinical-stage, Biopharmaceutical Company developing novel therapeutics primarily to treat cancer. The Company primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that selectively disable and destroy abnormal blood vessels that provide solid tumours a means of growth and survival, and also are associated with visual impairment in a number of ophthalmological diseases and conditions. OXiGENE Inc. (NASDAQ:OXGN) weekly performance is 106.80%. On last trading day company shares ended up $4.26. OXiGENE Inc. (NASDAQ:OXGN) distance from 50-day simple moving average (SMA50) is 65.18%. Analysts mean target price for the company is $1.20.